Subscribe To
IOVA / Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade)
Content Topics
Iovance
Biotherapeutics
Navigates
Regulatory
Delays
With
Biotherapeutics
Strategic
Finesse
rating
Upgrade
Stock
IOVA
IOVA News
By GlobeNewsWire
October 31, 2023
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev more_horizontal
By Seeking Alpha
October 22, 2023
Iovance Biotherapeutics: Testing Shareholders' Patience
Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on more_horizontal
By Seeking Alpha
October 19, 2023
Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better
Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better more_horizontal
By GlobeNewsWire
September 27, 2023
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting
SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de more_horizontal
By Seeking Alpha
September 18, 2023
Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade)
Iovance Biotherapeutics shows promise in T-cell therapies for solid tumors despite FDA delays; robust financials with a cash runway of 13.1 months. In more_horizontal
By The Motley Fool
September 18, 2023
Why Shares of Iovance Biotherapeutics Jumped Monday
Iovance's lead therapy lifileucel still has a chance at an early approval to treat advanced melanoma. Lifileucel is also being tested to treat several more_horizontal
By The Motley Fool
September 15, 2023
Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today
At first glance, the latest regulatory news is a setback. However, there were more than a few silver linings in this development. more_horizontal
By Invezz
September 15, 2023
IOVA stock price soared but risk/reward is unfavourable for now
Iovance Biotherapeutics (NASDAQ: IOVA) stock price defied gravity on Friday as investors cheered the latest FDA update about its drug. The shares jump more_horizontal